Certara (NASDAQ:CERT) Shares Up 5.9%

Certara, Inc. (NASDAQ:CERTGet Rating) shares shot up 5.9% during trading on Friday . The company traded as high as $15.02 and last traded at $15.00. 29,440 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 864,170 shares. The stock had previously closed at $14.16.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CERT. Morgan Stanley dropped their price objective on Certara from $24.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 24th. Barclays dropped their price target on Certara from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, October 6th. SVB Leerink dropped their price target on Certara from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 10th. Credit Suisse Group dropped their price target on Certara from $22.00 to $20.00 and set an “outperform” rating on the stock in a research note on Monday, November 14th. Finally, Piper Sandler reduced their price target on Certara from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.14.

Certara Stock Up 6.4 %

The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.99 and a current ratio of 3.99. The firm has a market cap of $2.41 billion, a PE ratio of -502.33, a PEG ratio of 1.00 and a beta of 1.09. The stock has a fifty day moving average price of $13.18 and a 200-day moving average price of $17.36.

Insider Transactions at Certara

In other news, Director Matthew M. Walsh sold 12,059 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $14.74, for a total transaction of $177,749.66. Following the completion of the sale, the director now owns 167,901 shares in the company, valued at approximately $2,474,860.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.02% of the company’s stock.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Horizon Advisors Inc. lifted its position in Certara by 9,193.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,487 shares of the company’s stock worth $32,000 after acquiring an additional 1,471 shares in the last quarter. Benjamin Edwards Inc. lifted its position in Certara by 9,338.1% during the 1st quarter. Benjamin Edwards Inc. now owns 1,982 shares of the company’s stock worth $43,000 after acquiring an additional 1,961 shares in the last quarter. Captrust Financial Advisors lifted its position in Certara by 135.8% during the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock worth $99,000 after acquiring an additional 2,665 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Certara during the 1st quarter worth approximately $111,000. Finally, Heritage Wealth Management LLC acquired a new position in Certara during the 2nd quarter worth approximately $117,000. 77.42% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

See Also

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.